.png)
.png)
.png)
Upload Prescription
.png)
1 Strip = 10 Tablets
NIPRO JMI PharmaProduct Description
Emjenta contains a fixed-dose combination of Empagliflozin and Linagliptin, which provides a synergistic approach to managing type 2 diabetes by targeting two distinct physiological pathways. Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, promotes the renal excretion of glucose through the urine, while Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the body's natural incretin system to stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner. This dual mechanism not only offers robust glycemic control with a low risk of hypoglycemia but also provides significant cardiovascular and renal protection, alongside modest reductions in body weight and blood pressure. While generally well-tolerated, the combination requires monitoring for side effects such as urinary tract infections and yeast infections associated with SGLT2 inhibition, and it is typically administered as a convenient once-daily tablet.
Similar Products
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
Previously Browsed Items
.jpg)
.jpg)
.png)
.jpg)
.jpg)
.jpg)
.jpg)
Copyright ﾃつｩ 2026 | Saf1 Rx | All rights reserved
.jpg)
.jpg)
.jpg)
